DMAC vs HON · $157.4M cap vs P/E 36, rev $9.72B
DiaMedica Therapeutics Inc (DMAC) versus Honeywell International Inc (HON) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Honeywell International Inc (HON) is a conglomerates company listed on NASDAQ. It is led by Vimal Kapur.
DMAC does not have a complete income-statement cache yet.
Latest reported HON revenue for 2026-06-30 was $9.72B. Net income was $5.68B. Revenue was up 6.3% from 2026-03-31 to 2026-06-30. HON currently screens at market cap $144.86B and trailing P/E 36.5.
DMAC currently screens at market cap $157.4M. HON currently screens at market cap $144.86B and trailing P/E 36.5.
Not investment advice. Open the DMAC and HON stock pages for the full models.
Not investment advice.